After two separate trials, it was clear that 10mg Lipitor
(atorvastatin) was having an adverse effect on my glucose
control, which is typically in the high normal/low impaired
range since I lost weight. Pravachol (pravastatin) doesn't
have such an effect on me, but it doesn't lower my
cholesterol anywhere near as well either. (I haven't had any
other significant side effects from either drug except some
very mild and short-lived aching in one thigh.)
I originally posted about this late last year, starting a
thread called "Lipitor Clearly Worsening Glucose Control".
(Web link via Google: groups.google.comgroupsOpen ↗
pitor+clearly+worsening+glucose+control+group:misc.health.-
diabetes )
Since starting that original thread, I found the following
rodent study abstract on Medline. Granted, it was a small
exploratory study on animals, but the results parallel mine
so very closely, namely:
(1) "Subjects" started with "borderline" glucose
intolerance, (2) Lipitor increased post-meal glucose
sometimes while Pravachol didn't,
(2) This effect took a few weeks to emerge, and (4)
(Presumably), neither statin affected fasting glucose.
I wish someone would do a really GOOD, human study on this,
but who would fund it? Maybe in pre-diabetic or (thus far)
mildly diabetic people, even a minor deterioration in
glucose tolerance from Lipitor could outweigh the drug's
protective benefits.
I've set off the key conclusions below with asterisks.
Rick
ncbi.nlm.nih.govquery.fcgiOpen ↗
db=pubmed&dopt=Abstract&list_uids=14646170
Biol Pharm Bull. 2003 Dec;26(12):1681-4.
Effects of atorvastatin [Lipitor] and pravastatin
[Pravachol] on glucose tolerance in diabetic rats mildly
induced by streptozotocin.
Kanda M, Satoh K, Ichihara K.
Department of Pharmacology, Hokkaido College of Pharmacy,
Katsuraoka, Otaru, Japan.
Effects of atorvastatin [Lipitor] and pravastatin
[Pravachol] on glucose tolerance in mildly induced diabetic
rats by streptozotocin at 24 mg/kg, i.v. were studied. Non-
diabetic and diabetic rats were given orally 0.5%
carboxymethylcellulose (control), 8 mg/kg atorvastatin or 8
mg/kg pravastatin once a day for 6 weeks. An oral glucose
tolerance test (OGTT) was carried out 1, 2, 3, and 6 weeks
after the administration. The blood glucose and plasma
insulin levels measured before OGTT in the diabetic rats
were not different from those in the non-diabetic rats.
However, the hyperglycemic response to OGTT in the diabetic
rats significantly exceeded that in the non-diabetic rats.
The plasma insulin increased by OGTT in the diabetic rats
appeared to be lower than that in the non-diabetic rats.
Statin treatments for 1 week did not modify the OGTT-induced
hyperglycemia appreciably, although there were some
significant differences. *******More than 2 weeks after
administration, the blood glucose levels at several time
points after a glucose intake in the atorvastatin-treated
diabetic rats were significantly higher than the respective
levels in the control diabetic rats. Neither atorvastatin
nor pravastatin modified the OGTT-induced insulin secretion.
Statins, especially atorvastatin, may influence the glucose
tolerance in mildly induced diabetic rats without
alterations of insulin secretion.******